Page 6 - Sharon Shacham News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sharon shacham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sharon Shacham Today - Breaking & Trending Today

Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcript

Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , South Korea , Mike Mason , Stephen Mitchener , Peter Lawson , Michael Mason , Sohanya Cheng , Wei Ji Chang , Eric William Joseph Jpmorgan , Brian Corey Abrahams , Jatin Shah , David Lebowitz , Kevin Strang , Maury Raycroft , Joe Rayne , Colleen Kusy , Richard Paulson , Brian Abrams , Jonathan Chang , Sharon Shacham , Deric Joseph , Morgan Stanley , Peter Richard Lawson Barclays Bank Analyst , Mono Pharmaceuticals , European Medicine Agency Committee ,

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
News provided by
Share this article
Share this article
NEWTON, Mass., May 19, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company s first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old and patients with RAS-mutated mul ....

United States , University Hospital , Xavier Leleu , Christopherj Walker , Mike Dolph , Talia Golan , Shannon Westin , Sangmin Lee , Yasaman Demastani , Cesar Serrano , Darrell White , Cristina Gasparetto , Thierry Facon , Yazmin Odia , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Virginia University School Of Medicine Neurology Neurosurgery , American Society Of Clinical Oncology , Weill Cornell Medical College , Selective Inhibitor Of Nuclear , University Hospitals Leuven , Leuven Cancer Institute , Miami Cancer Institute , Karyopharm Selective Inhibitor Of Nuclear Export , Mcgill University , Information Department ,

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , University Hospital , Xavier Leleu , Christopherj Walker , Mike Dolph , Talia Golan , Shannon Westin , Sangmin Lee , Yasaman Demastani , Cesar Serrano , Darrell White , Cristina Gasparetto , Thierry Facon , Yazmin Odia , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Virginia University School Of Medicine Neurology Neurosurgery , American Society Of Clinical Oncology , Weill Cornell Medical College , Selective Inhibitor Of Nuclear , University Hospitals Leuven , Leuven Cancer Institute , Miami Cancer Institute , Karyopharm Selective Inhibitor Of Nuclear Export , Mcgill University , Information Department ,

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership and Global Strategic Experience
Michael G. Kauffman to Remain on Board of Directors and Assume New Role as Senior Clinical Advisor
News provided by
Share this article
Share this article
NEWTON, Mass., May 3, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Richard Paulson as Karyopharm s President and Chief Executive Officer, effective May 3, 2021. Mr. Paulson will also remain a member of the Board of Directors. He will succeed Michael G. Kauffman, MD, PhD, as Chief Executive Officer and Sharon Shacham, PhD, MBA, as President. Dr. Kauffman will continue in ....

United States , South Africa , Czech Republic , Ian Karp , Richard Paulson , Michaelg Kauffman , Barry Greene , Andrew Lee , Sharon Shacham , Company Scientific Advisory Board , Takeda Pharmaceutical Company , University Of Saskatchewan , University Of Toronto , Company As Senior Clinical Advisor , Pfizer Inc , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , Corporate Governance Compliance Committee , Ipsen Pharmaceuticals Inc , Chief Executive Officer , Senior Clinical ,

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million
Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021
Richard Paulson Appointed Next President and Chief Executive Officer of Karyopharm
Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article
NEWTON, Mass., May 3, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including ....

United States , Michaelg Kauffman , Richard Paulson , Sharon Shacham , Selective Inhibitor Of Nuclear Export , American Society Of Clinical Oncology , Takeda Pharmaceutical Company , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , Committee For Medicinal Products Human Use , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Progress Towards The International Expansion , Exchange Commission , Ipsen Pharmaceuticals Inc , Development For Solid Tumors , European Medicines Agency , European Commission Ec Grants Conditional Marketing Authorization , Israeli Ministry Of Health , Karyopharm Therapeutics , Chief Executive Officer , Paulson Named Next President , Executive Vice President , Ipsen Pharmaceuticals ,